To account for differences in baseline pain, pain scores were converted into maximal pain intensity difference (PID) and summed pain intensity difference (SPID). The PID reflects peak analgesic effect, and the SPID is the area under the time-pain reduction curve.9 This study found that buccal oxycodone, but not placebo, was associated with a significant decrease in SPID 3.5 hours after the first administered dose. In contrast, PID scores for oxycodone and placebo were not significantly different. However, the clinically significant level of pain reduction, as measured by SPID or PID, was not discussed. Lee et al10 reported that a 3-cm reduction in PID, as measured on a visual analog scale, is the minimum clinically significant difference in pain control. Farrar et al11 indicated that a 33% reduction in percent SPID (SPID/maximum possible SPID) was clinically relevant. However, these calculations cannot be performed with the data provided. At both predose and postdose assessments, no significant differences in sensitivity, specificity, and diagnostic accuracy were found between oxycodone and placebo groups. We were unable to reproduce Table 2 from the data provided in Figure 2. It is not clearly stated (1) when patients were assigned to the observation or laparotomy group and (2) when they were classified as having a surgical or nonsurgical disease. However, calculations of sensitivity, specificity, and diagnostic accuracy based on postdose assessments are not significantly altered by reassigning patients using different time frames for observation vs laparotomy group assignment or surgical vs nonsurgical disease group assignment.